Expert perspectives on prostate cancer with deference to clinical presentations, diagnosis, and prognosis.
The Impact of ADT for Prostate Cancer on Survival and Patient Well-Being
February 14th 2025Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of international research on androgen deprivation therapy (ADT) for prostate cancer presented at this year’s American Society of Clinical Oncology Genitourinary Cancers Symposium.
Read More
Using Active Surveillance to Spare Men From Unneeded Prostate Cancer Treatment
August 31st 2024Advances in technology have made active surveillance in men with prostate cancer possible and prevented treatment for men who don’t need it, said Matthew Nielsen, MD, FACS, chair, Department of Urology, University of North Carolina School of Medicine.
Read More
Dr Jun Gong: Improved Access Closes the Gaps Between Black, White Men With Prostate Cancer
February 18th 2024Despite socioeconomic and biological differences that contribute to disparities between Black men and White men with prostate cancer, improved access has been shown to reduce the gaps, explained Jun Gong, MD, of Cedars Sinai.
Read More
Surgery, Radiation for PCa Show Equal Efficacy in Candidates for Renal Transplantation
September 27th 2023A recent study suggests that patients with high-risk prostate cancer (PCa) in need of renal transplantation should receive cancer treatment before their transplants, as surgery and radiation treatment for localized PCa appear to be equally effective in this patient population.
Read More
Racial Differences in Chemokine Expression May Contribute to Prostate Cancer Disparities
September 22nd 2023Researchers found that analyzing certain chemokine levels may help explain racial disparities in prostate cancer lethality, and that neutralizing such chemokines could potentially benefit prostate cancer treatment.
Read More
Cabozantinib Plus Atezolizumab Significantly Improves PFS in Metastatic CRPC
September 16th 2023Combination treatment with cabozantinib and atezolizumab did not produce any new safety signals in the treatment of those with metastatic castration-resistant prostate cancer in the phase 3 CONTACT-02 trial.
Read More